The 2025-2030 World Outlook for Advanced Wound Care

The 2025-2030 World Outlook for Advanced Wound Care

This study covers the world outlook for advanced wound care across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of advanced wound care as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 3M Company, Acelity, ACELL, Advanced BioHealing, Advancis Medical UK, Alliqua Biomedical, Anika Therapeutics, Arobella, Aspen, Avery Dennison Corporation, Avista Capital Partners, Avita Medical, B. Braun, Bace Comércio Internacional, Baxter, Beckton Dickinson, Boehringer, Brennan Medical, Bristol-Myers Squibb, BSN Medical, C.R. Bard, Cardinal Health, Celularity, Center for Disease Control (CDC), Changchun JA Biotech, Codman Neurosurgery, Coloplast, ConvaTec, Covalon, Covidien, Crawford Healthcare, Daewoong Pharmaceutical, DeOst Group, Derma Sciences, DeRoyal Industries, Devon Medical Products, Dr. Suwelack Skin & Health Care, EdixoMed, ER Squibb & Sons, Essity Aktiebolag (BSN Medical GMBH), FarrowMed, Food and Drug Administration (FDA), Fraunhofer Institute, Genadyne, Generex Biotechnology, Genewel, Genzyme, GHD GesundHeits GMBH Deutschland, Hartmann, Healthpoint, Hill-Rom Holdings, Inc., Histocell, Hollister, Human Bioscience, Immodulon, Innocoll, Innovative Therapies, Integra Life Science, International Diabetes Federation (IDF), Johnson & Johnson, JoViPak, KCI, Kerecis, Kimberley-Clark, Kinetic Concepts, Lescarden, LifeCell, Lightwave Technologies, Lohmann & Rauscher GmbH & Company, Luqa Pharmaceuticals, MacroCure, Medela, Mediq, MediWound, Medline, Medtronic, Metasurg, MIL Laboratories Pvt, Ltd., MiMedx, Ministry of Health, Labour, and Welfare (MHLW), Misonix, Mlnlycke Health Care AB, Molnlycke, Mölnlycke, Molnlycke healthcare, Mölnlycke Healthcare, Mo-Sci, Mpm Medical, Mundipharma, Nanotherapeutics, Nordic Capital Partners, Nuo Therapeutics, NuTech Medical, Olaregen Therapeutix, Inc., Organogenesis, Osiris Therapeutics, Paul Hartmann, Pharmaceuticals and Medical Devices Agency (PMDA), Politec Saúde, Prizm Medical, Prospera, Regentys Corporation, Sanuwave Health, SastoMed GmbH, Shandong Wego Newlife Medical Devices, SHIELD Line, Shire, Smith & Nephew, Snap, Sorbion, Spiracur, Sundance Enterprises, Inc., Synapse Microcurrent, Systagenix, Talley Group, TEI Biosciences, Terumo Corporation, The Harvard Drug Group (THDG), Tissue Analytics, TRIAGE MEDITECH, URGO, Vancive Medical Technologies, Vomaris Innovations, Welcare Industries, WINNER Medical Company, Ltd., World Health Organisation (WHO), Wound Management Technologies, Wright Therapy Products, Inc., Zhejiang Top Medical, and Zimmer Biomet. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).